Arcturus Agrees to Buy myNEO, Reports Interim Liver Disorder Data
By Elias SchisgallArcturus Therapeutics Holdings agreed to acquire the artificial-intelligence drug discovery company myNEO and reported interim data from a phase 2 trial of a treatment for a metabolic liver disorder.Arcturus said the acquisition of myNEO, a company it has worked with since 2024, w…